Board of directors
Martin Nicklasson, Ph.D.
Member of the board of directors
Nationality: Swedish | Year of Birth: 1955
Martin Nicklasson, Ph.D., has been a member of the
board of directors since 2013. He is also chairman of the compensation committee and a member of the audit committee. He is independent in accordance with the Swiss Code of Best Practice for Corporate Governance.
Mr. Nicklasson was chairman of the board of Kymab Group Ltd. from 2017 to April 2021, member of the board of Orexo AB from 2012 to 2020 and served as president and CEO of Biovitrum AB and Swedish Orphan Biovitrum AB from 2007 to 2010. From 1999 to 2007 he held various executive vice president positions and was a member of the executive committee of AstraZeneca Plc.
Mr. Nicklasson is chairman of the board of Zealand Pharma A/S and chairman of the board of Nykode Therapeutics AS. He also serves as consultant at Excore Consulting KB.
Mr. Nicklasson is a certified pharmacist and holds a doctorate in Pharmaceutical Technology from the University of Uppsala. He is an honorary Associate Professor at the Pharmaceutical Faculty of the University of Uppsala.